ValiRx Plc (VAL):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:ValiRx Plc (VAL) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7347
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:36
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ValiRx Plc (ValiRx) is a life science company that develops therapeutics for the treatment of clinical stage cancer. The company’s products include VAL201-prostate cancer, VAL401-lung cancer, GeneICE – BCL-2, and NAV3 cancer screening test. It uses GeneICE technology, which enables silencing of specific genes by targeted histone deacetylation for chromatin condensation. ValiRx’s ValiMedix division sells and distributes oncology therapeutics. The company’s ValiPharma division is a therapeutics division that provides technologies for the treatment of cancer. Its’s ValiFinn division offers research and development services. The company also develops clinical trials, which is used to treat hormone induced refractory prostate cancer and other conditions of hormone. ValiRx is headquartered in London, the UK.

ValiRx Plc (VAL) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ValiRx Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
ValiRx Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
ValiRx Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
ValiRx Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 8
ValiRx Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
ValiRx Plc, Medical Equipment, Deal Details 10
Asset Purchase 10
ValiRx Acquires Biomarkers Business Unit From Pharmatest Services For US$0.2 Million 10
Equity Offering 12
ValiRx Raises USD1.5 Million in Private Placement of Shares 12
ValiRx Raises USD1.33 Million in Private Placement of Shares 13
ValiRx Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 14
ValiRx Raises USD0.1 Million in Private Placement of Shares up on Exercise of Warrants 15
ValiRx Raises USD0.7 Million in Private Placement of Shares 16
Valirx Raises Funds in Private Placement of Shares 17
Valirx Raises USD1.4 Million in Private Placement of Shares 18
Valirx Raises USD1.58 Million in Placing of Ordinary Shares 19
Acquisition 20
ValiRx Divests Its Stake In VolitionRx For US$0.6 Million 20
ValiRx Plc – Key Competitors 21
ValiRx Plc – Key Employees 22
ValiRx Plc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Joint Venture 23
Recent Developments 24
Financial Announcements 24
Sep 25, 2018: VALIRX: Half yearly report for the period ended 30 June 2018 24
Apr 10, 2018: ValiRx: Final Results for the Year Ended 31 December 2017 26
Sep 26, 2017: Valirx: Half Yearly Report For The Period Ended 30 June 2017 30
May 05, 2017: ValiRx: Final Results for the Year Ended 31 December 2016 32
Legal and Regulatory 35
Apr 18, 2017: ValiRx: Change of Registered Office 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
ValiRx Plc, Medical Equipment, Key Facts, 2017 2
ValiRx Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
ValiRx Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
ValiRx Plc, Medical Equipment Deals By Type, 2012 to YTD 2018 6
ValiRx Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
ValiRx Plc, Deals By Market, 2012 to YTD 2018 8
ValiRx Plc, Medical Equipment, Deals Summary, 2012 to YTD 2018 9
ValiRx Acquires Biomarkers Business Unit From Pharmatest Services For US$0.2 Million 10
ValiRx Raises USD1.5 Million in Private Placement of Shares 12
ValiRx Raises USD1.33 Million in Private Placement of Shares 13
ValiRx Raises USD0.05 Million in Private Placement of Shares up on Exercise of Warrants 14
ValiRx Raises USD0.1 Million in Private Placement of Shares up on Exercise of Warrants 15
ValiRx Raises USD0.7 Million in Private Placement of Shares 16
Valirx Raises Funds in Private Placement of Shares 17
Valirx Raises USD1.4 Million in Private Placement of Shares 18
Valirx Raises USD1.58 Million in Placing of Ordinary Shares 19
ValiRx Divests Its Stake In VolitionRx For US$0.6 Million 20
ValiRx Plc, Key Competitors 21
ValiRx Plc, Key Employees 22
ValiRx Plc, Subsidiaries 23
ValiRx Plc, Joint Venture 23

List of Figures
ValiRx Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
ValiRx Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
ValiRx Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
ValiRx Plc, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
ValiRx Plc, Medical Equipment, Deals By Year, 2012 to YTD 2018 5
ValiRx Plc, Medical Equipment, Deals by Type, 2012 to YTD 2018 6
ValiRx Plc, Medical Equipment, Deals By Region, 2012 to YTD 2018 7
ValiRx Plc, Medical Equipment, Deals by Market, 2012 to YTD 2018 8

★海外企業調査レポート[ValiRx Plc (VAL):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AMEWAS, Inc.:企業の戦略・SWOT・財務分析
    AMEWAS, Inc. - Strategy, SWOT and Corporate Finance Report Summary AMEWAS, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Swedbank AB:企業の戦略・SWOT・財務情報
    Swedbank AB - Strategy, SWOT and Corporate Finance Report Summary Swedbank AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Cellumed Co Ltd (049180):医療機器:M&Aディール及び事業提携情報
    Summary Cellumed Co Ltd (Cellumed), formerly Korea Bone Bank Inc is a biotechnology company that develops bone graft substitution based on human tissue graft. The company offers allograft tissue products such as bio-clearant, a clearant process that treats tissues with patented chemicals and sterili …
  • Brunei National Petroleum Company Sendirian Berhad:石油・ガス:M&Aディール及び事業提携情報
    Summary Brunei National Petroleum Company Sendirian Berhad (PetroleumBRUNEI) is an oil and gas company that provides exploration and production of oil and gas. The company offers engineering, procurement, construction, installation, commissioning services, and others. It provides oilfield services, …
  • KARL STORZ SE & Co KG:企業の戦略的SWOT分析
    KARL STORZ SE & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Walmart Inc:企業のM&A・事業提携・投資動向
    Walmart Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Walmart Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Yakult Honsha Co Ltd (2267):企業の財務・戦略的SWOT分析
    Yakult Honsha Co Ltd (2267) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • IDT Biologika GmbH-製薬・医療分野:企業M&A・提携分析
    Summary IDT Biologika GmbH (IDT Biologika), a subsidiary of Klocke Pharma-Service GmbH, is a manufacturer of vaccines and bio-pharmaceuticals products. It offers services which include integrated development and manufacturing services in four major areas of animal health, vaccines, pharmaceuticals a …
  • Corporation Bank:戦略・SWOT・企業財務分析
    Corporation Bank - Strategy, SWOT and Corporate Finance Report Summary Corporation Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Genting Singapore Plc:戦略・SWOT・企業財務分析
    Genting Singapore Plc - Strategy, SWOT and Corporate Finance Report Summary Genting Singapore Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Tuas Power Ltd:企業の戦略的SWOT分析
    Tuas Power Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Dubai Electricity and Water Authority:企業の戦略的SWOT分析
    Dubai Electricity and Water Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Apotex Inc:企業の戦略的SWOT分析
    Apotex Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Hovid Berhad (HOVID):企業の財務・戦略的SWOT分析
    Hovid Berhad (HOVID) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Bio-Path Holdings Inc (BPTH):医療機器:M&Aディール及び事業提携情報
    Summary Bio-Path Holdings Inc (Bio-Path) is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen (Liposomal Grb2 Antisense) …
  • C-TRI Co Ltd (047920):製薬・医療:M&Aディール及び事業提携情報
    Summary C-TRI Co Ltd (C-TRI), a subsidiary of DAE HWA Pharmaceutical Co Ltd, is a pharmaceutical company that offers development of new peptide drugs. The company’s products include ethicals, over-the-counter drugs, Quasi-drugs, cosmetics, amendments, pharmaceuticals, taltirelin, desmopressin, presc …
  • Jack in the Box Inc (JACK):企業の財務・戦略的SWOT分析
    Jack in the Box Inc (JACK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Metlifecare Ltd (MET)-製薬・医療分野:企業M&A・提携分析
    Summary Metlifecare Ltd (Metlifecare) is a healthcare service provider that owns and manages retirement villages to older citizens in New Zealand. The center provides retirement villages provide services such as healthcare services, security, community and companionship, maintenance free living and …
  • CA Inc:企業の戦略・SWOT・財務分析
    CA Inc - Strategy, SWOT and Corporate Finance Report Summary CA Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, prov …
  • American Armed Forces Mutual Aid Association:企業の戦略的SWOT分析
    American Armed Forces Mutual Aid Association - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆